Filter by Category: In Vitro Activity
In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020)
In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020). Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1529
Activity of Cefiderocol and Comparators against European Enterobacterales Including Carbapemen-Resistant Isolates
Activity of Cefiderocol and Comparators against European Enterobacterales Including Carbapemen-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1563
Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase
Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1047
Activity of Cefiderocol and Comparators against US Enterobacterales, Including Carbapenem-Resistant Isolates
Activity of Cefiderocol and Comparators against US Enterobacterales, Including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1591
Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals
Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1048
In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected from Europe during 2019-2020
In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected from Europe during 2019-2020. Lead author: SJR Arends, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2122
Five Years of Analysis of the In Vitro Activity of Tedizolid against a Worldwide Collection of Indicated Species Causing Clinical Infections: Results from the Surveillance of Tedizolid Activity and Resistance (STAR) Program
Five Years of Analysis of the In Vitro Activity of Tedizolid against a Worldwide Collection of Indicated Species Causing Clinical Infections: Results from the Surveillance of Tedizolid Activity and Resistance (STAR) Program. Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #264
Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019)
Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1626
Activity of KBP-7072, a Novel Aminomethylcycline Antibacterial, and Tetracycline Class Comparators Against 1,057 Bacterial Pathogens Collected Worldwide During 2019
Activity of KBP-7072, a Novel Aminomethylcycline Antibacterial, and Tetracycline Class Comparators Against 1,057 Bacterial Pathogens Collected Worldwide During 2019. Lead author: M Huband presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1510
In Vitro Activity of a Novel Aminomethylcycline Antibacterial (KBP-7072) against Clinical Isolates with Molecularly Characterized Tetracycline Resistance Mechanisms
In Vitro Activity of a Novel Aminomethylcycline Antibacterial (KBP-7072) against Clinical Isolates with Molecularly Characterized Tetracycline Resistance Mechanisms. Lead author: RE Mendes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2189
Activity of Oritavancin and Comparators against a Contemporary Collection of Enterococcus spp. Clinical Isolates from Europe (2015-2019)
Activity of Oritavancin and Comparators against a Contemporary Collection of Enterococcus spp. Clinical Isolates from Europe (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1616
Activity of Cefiderocol and Comparators against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates
Activity of Cefiderocol and Comparators against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1606
Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. by Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Snippes Vagnone P, Witwer M, Castanheira M and Johnson JR. J. Antimicrob. Chemother.: in press, 2021.
Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019).
Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019). by Carvalhaes CG, Sader HS, Rhomberg PR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 92-100
In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains.
In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Parr TR and Castanheira M. published in Antimicrob. Agents Chemother. 2020; 65 (1): e00742
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Sader HS, Carvalhaes CG, Arends SJR, Castanheira M and Mendes RE. published in J. Antimicrob. Chemother. 2021; 76 (3): 659-666
Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species.
Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. by Sader HS, Carvalhaes CG, Streit JM, Arends SJR and Mendes RE. published in J Glob Antimicrob Resist. 2021; 24: 48-52
Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)
Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). by Sader HS, Carvalhaes CG and Mendes RE. published in Int. J. Infect. Dis. 2021; 102: 524-528
In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe.
In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe. by Carvalhaes CG, Duncan LR, Wang W and Sader HS. published in Antimicrob. Agents Chemother. 2020; 64 (11): e01195
Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia.
Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. by Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, Patel S, Mendes RE and Wenzler E published in Antimicrob. Agents Chemother. 2020; 64 (9): e00559
In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains.
In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Parr TR and Castanheira M. published in Antimicrob. Agents Chemother.: in press, 2020.
Ceftaroline Activity against Staphylococcus aureus Isolated from Patients with Infective Endocarditis Worldwide (2010-2019)
Ceftaroline Activity against Staphylococcus aureus Isolated from Patients with Infective Endocarditis Worldwide (2010-2019). Lead author: HS Sader, presented at CHEST 2020, October 18-21, Virtual Conference
Poster #P0447
Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus causing Pneumonia in Patients with and without Cystic Fibrosis.
Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus causing Pneumonia in Patients with and without Cystic Fibrosis. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #347
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #315
Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019).
Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278
Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens
Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: Dee Shortridge. Presented at IDWeek 2020.
Poster #1620
Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides
Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides. Primary Author: Helio Sader. Presented at IDWeek 2020.
Poster #1278
In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms
In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.
Presentation #26
Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019
Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019. Lead author: LR Duncan, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1595
Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258
Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1589
Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster # 1547
Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019)
Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1463
Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019)
Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #333
In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019)
In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019). Lead author: MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1253
Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens
Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1620
Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019)
Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590
Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals
Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Lead author: M Castanheira presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1443
In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018).
In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). by Huband MD, Lindley JM, Mendes RE, Fedler KA, Benn VJ, Zhang J, Zhong G, Li L, Zhang M, Tan X and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (4): 115191
Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019.
Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019. by Sader HS, Streit JM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 99 (1): 115195
Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide.
Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide. by Sader HS, Duncan LR, Arends SJR, Carvalhaes CG and Castanheira M. published in Antimicrob. Agents Chemother.: 2020; 64 (11): e01433
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. by Pfaller MA, Shortridge D, Arends SJR, Duncan LR, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (1): 115101.
Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection
Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection Lead author: D Shortridge presented at ASM Microbe 2020, June 18-22, Chicago IL, USA
Poster #3804
Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides.
Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. by Castanheira M, Sader HS, Mendes RE and Jones RN. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02418
In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates.
In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. by Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q and Flamm RK. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02375
Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019)
Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019). Lead author: MD Huband. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1019.
Poster #P1143
Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019)
Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2359)
Poster #P1174
Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018.
Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. by Flamm RK, Duncan LR, Hamed KA, Smart JI, Mendes RE and Pfaller MA. published in Antimicrobial agents and chemotherapy. in press, 2020.
Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018.
Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018. by Castanheira M, Doyle TB, Kantro V, Mendes RE and Shortridge D published in Antimicrob. Agents Chemother. 2020; 64 (2): 01951
Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018
Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018. by Carvalhaes CG, Shortridge D, Sader HS and Castanheira M. published in Antimicrob. Agents Chemother. 2020; 64 (3):e02177
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2019; 96: 114833